Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples

Area of Science:

• Oncology
• Biomarker Discovery
• Gastroenterology

Background:

• Early detection of pancreatic ductal adenocarcinoma (PDAC) is critical for improving patient survival rates.
• Current biomarkers, like carbohydrate antigen 19-9 (CA 19-9), have limitations in early PDAC diagnosis.
• Tissue polypeptide specific antigen (TPS) has been investigated as a potential alternative biomarker.

Purpose of the Study:

• To evaluate the potential of Tissue polypeptide specific antigen (TPS) as an early detection biomarker for pancreatic ductal adenocarcinoma (PDAC).
• To compare TPS levels in pre-diagnostic plasma samples with those from healthy controls and at the time of PDAC diagnosis.

Main Methods:

• A case-control study utilizing pre-diagnostic plasma samples from 267 future PDAC patients and 320 matched healthy controls.
• Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma TPS levels.
• Longitudinal analysis was performed on a subset of individuals with multiple pre-diagnostic samples.

Main Results:

• Circulating TPS levels were low in both pre-diagnostic PDAC samples and healthy controls.
• TPS levels were significantly increased at the time of PDAC diagnosis compared to pre-diagnostic samples.
• Logistic regression analysis adjusted for age showed a significant increase in TPS at diagnosis (OR 1.03; 95% CI: 1.01-1.05).

Conclusions:

• Tissue polypeptide specific antigen (TPS) levels rise late in the progression of pancreatic ductal adenocarcinoma (PDAC).
• TPS does not demonstrate potential as a biomarker for the early detection of PDAC.
• Further research may be needed to explore other biomarkers for early PDAC diagnosis.